Patient-specific cancer therapy
Strike Pharma AB commercializes a unique platform technology for immunotherapy, based on research at Uppsala University in close collaboration with SciLifeLab Drug Discovery and Development Platform and the Swedish University of Agricultural Sciences.
We are developing the next generation of personal immunotherapies to fight cancer and other serious diseases in patients with the highest severity of disease.
Strike Pharma was formed via UU Invest’s pre-incubation process in ”UU Projekt”.
START YEAR
2020
INVESTMENT
2021
VD
Mårten Winge
Contact
marten.winge@strikepharma.com
